查看所有供应商和价格请点击:
2079108-44-2生产厂家
2079108-44-2价格
化源商城直购
[1]. D V T Catenacci, et al. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A. ESMO Open. 2022 Oct;7(5):100563.